Back to discover
Drug

Nusinersen sodium

Approved · EMA

Also known as nusinersen (as sodium).

RxNorm1869891
1
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Nusinersen sodium
Aliases & brands
nusinersen (as sodium)
RxNorm CUI
1869891
Regulatory jurisdictions
ema

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2017-05-30
Latest approval
2017-05-30
Authorities
EMA
Total events
1
emaEuropean Medicines Agency· 1 event
2017-05-30Accelerated approval
Accelerated approval: Spinraza (EMA)

Indication: Spinraza is indicated for the treatment of 5q Spinal Muscular Atrophy.

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • Regulatory event sources are credited in the Regulatory Timeline above.